Wellington Shields Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-69,535
Closed -$115K 322
2025
Q3
$115K Sell
69,535
-21,310
-23% -$38K 0.02% 274
2025
Q2
$107K Sell
90,845
-49
-0.1% -$90 0.02% 266
2025
Q1
$196K Buy
90,894
+5,059
+6% +$12.4K 0.04% 223
2024
Q4
$243K Sell
85,835
-3,382
-4% -$16K 0.04% 215
2024
Q3
$550K Hold
89,217
0.1% 149
2024
Q2
$491K Sell
89,217
-3,000
-3% -$9.32K 0.09% 156
2024
Q1
$333K Sell
92,217
-40,929
-31% -$220K 0.06% 191
2023
Q4
$953K Sell
133,146
-20,309
-13% -$97.7K 0.12% 109
2023
Q3
$393K Sell
153,455
-25,000
-14% -$59.2K 0.05% 161
2023
Q2
$446K Sell
178,455
-1,688
-0.9% -$4.54K 0.05% 156
2023
Q1
$418K Sell
180,143
-26,005
-13% -$50.1K 0.05% 164
2022
Q4
$369K Sell
206,148
-12,099
-6% -$24K 0.04% 173
2022
Q3
$567K Buy
218,247
+4,997
+2% +$16.1K 0.13% 129
2022
Q2
$610K Sell
213,250
-5
-0% -$22 0.08% 126
2022
Q1
$1.73M Sell
213,255
-5,600
-3% -$44K 0.19% 77
2021
Q4
$1.75M Sell
218,855
-6,972
-3% -$69.4K 0.22% 95
2021
Q3
$2.69M Buy
225,827
+1
+0% +$14 0.37% 53
2021
Q2
$3.5M Buy
225,826
+2,649
+1% +$44.6K 0.42% 46
2021
Q1
$5.36M Buy
223,177
+16,000
+8% +$449K 0.51% 41
2020
Q4
$6.11M Buy
207,177
+64,704
+45% +$1.41M 0.82% 25
2020
Q3
$2.18M Buy
142,473
+10,298
+8% +$194K 0.35% 58
2020
Q2
$3.3M Buy
132,175
+617
+0.5% +$13.4K 0.53% 40
2020
Q1
$2.68M Hold
131,558
0.51% 43
2019
Q4
$4.07M Buy
131,558
+50
+0% +$1.62K 0.62% 34
2019
Q3
$4.39M Buy
131,508
+17,384
+15% +$558K 0.71% 26
2019
Q2
$3.65M Sell
114,124
-471
-0.4% -$15K 0.61% 33
2019
Q1
$3.29M Sell
114,595
-3,118
-3% -$109K 0.56% 37
2018
Q4
$4.73M Buy
117,713
+28,880
+33% +$1.09M 0.89% 17
2018
Q3
$4.15M Buy
88,833
+3,327
+4% +$232K 0.67% 24
2018
Q2
$7.04M Buy
85,506
+6,480
+8% +$437K 1.16% 9
2018
Q1
$3.29M Buy
79,026
+6,491
+9% +$242K 0.5% 41
2017
Q4
$2.36M Hold
72,535
0.37% 60
2017
Q3
$1.28M Sell
72,535
-72
-0.1% -$841 0.21% 107
2017
Q2
$762K Sell
72,607
-238
-0.3% -$2.53K 0.12% 162
2017
Q1
$1.03M Buy
72,845
+20,000
+38% +$272K 0.17% 132
2016
Q4
$608K Sell
52,845
-2,882
-5% -$39.5K 0.1% 180
2016
Q3
$619K Sell
55,727
-414
-0.7% -$4.54K 0.11% 178
2016
Q2
$657K Hold
56,141
0.11% 159
2016
Q1
$595K Buy
56,141
+9,605
+21% +$93K 0.1% 172
2015
Q4
$447K Sell
46,536
-12,450
-21% -$141K 0.08% 213
2015
Q3
$631K Sell
58,986
-184
-0.3% -$2.65K 0.11% 164
2015
Q2
$1.06M Hold
59,170
0.16% 125
2015
Q1
$872K Buy
59,170
+2,000
+3% +$31.5K 0.13% 146
2014
Q4
$760K Sell
57,170
-28,001
-33% -$439K 0.12% 167
2014
Q3
$1.52M Buy
85,171
+7,655
+10% +$136K 0.25% 81
2014
Q2
$1.4M Buy
77,516
+310
+0.4% +$5.62K 0.22% 94
2014
Q1
$1.41M Buy
77,206
+5,000
+7% +$94.6K 0.24% 81
2013
Q4
$1.21M Sell
72,206
-4,825
-6% -$81.6K 0.22% 92
2013
Q3
$1.39M Hold
77,031
0.27% 72
2013
Q2
$1.56M Buy
+77,031
New +$1.49M 0.28% 69

Other funds holding CASI

Wellington Shields Capital Management's CASI Position: Q4 2025 in Review

Wellington Shields Capital Management sold out of CASI Pharmaceuticals (CASI) in Q4 2025, closing a stake of 69,535 shares — an estimated $115K sold.

Wellington Shields Capital Management first reported a position in CASI in Q2 2013 and held it in 50 quarters. The position peaked at $7.04M in Q2 2018. 16 funds tracked by Wall St. Rank hold CASI as of Q4 2025.

  • Wellington Shields Capital Management reported no remaining CASI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wellington Shields Capital Management sold 69,535 CASI Pharmaceuticals shares in Q4 2025, an estimated $115K.
  • Wellington Shields Capital Management first reported a position in CASI Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Wellington Shields Capital Management's CASI Pharmaceuticals position peaked at $7.04M in Q2 2018.
  • 16 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2025.

Based on Wellington Shields Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.